{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T10:36:00Z","timestamp":1790678160300,"version":"4.1.0"},"reference-count":40,"publisher":"BMJ","issue":"2","license":[{"start":{"date-parts":[[2020,8,28]],"date-time":"2020-08-28T00:00:00Z","timestamp":1598572800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000031","name":"Institute of Human Development, Child and Youth Health","doi-asserted-by":"publisher","award":["APR 126377"],"award-info":[{"award-number":["APR 126377"]}],"id":[{"id":"10.13039\/501100000031","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012395","name":"Canadian Immunization Research Network","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/501100012395","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Arch Dis Child"],"accepted":{"date-parts":[[2020,7,19]]},"published-print":{"date-parts":[[2021,2]]},"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>To evaluate the effectiveness of two palivizumab programmes targeting high-risk infants, defined by prematurity, diagnosis of comorbidities and geography, and assess potential disparities by neighbourhood income.<\/jats:p><\/jats:sec><jats:sec><jats:title>Design<\/jats:title><jats:p>Controlled, interrupted time series.<\/jats:p><\/jats:sec><jats:sec><jats:title>Setting<\/jats:title><jats:p>Ontario, Canada.<\/jats:p><\/jats:sec><jats:sec><jats:title>Patients<\/jats:title><jats:p>We used linked health and demographic administrative databases to identify all children born in hospitals 1 January 1993 through 31 December 2016. Follow-up ended at the earliest of second birthday or 30 June 2017.<\/jats:p><\/jats:sec><jats:sec><jats:title>Intervention<\/jats:title><jats:p>Palivizumab-eligibility: child was born very preterm and \u22646 months old during respiratory syncytial virus (RSV) season; &lt;24 months old with significant chronic lung or congenital heart disease; or \u22646 months, born preterm or residents of remote regions.<\/jats:p><\/jats:sec><jats:sec><jats:title>Main outcome<\/jats:title><jats:p>Severe RSV-related illness, defined as hospitalisation or death with a diagnosis of bronchiolitis, RSV pneumonia or RSV.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>3\u2009million births and 87 000 RSV-related events were identified. Over the study period, rates of severe RSV-related illness declined 65.4% among the highest risk group, eligible infants &lt;6 months (230.6 to 79.8 admissions per 1000 child-years). Relative to changes among ineligible infants &lt;6 months, rates dropped 10.4% (95% CI \u221218.6% to 39.4%) among eligible infants immediately following introduction of a national palivizumab programme in 1998. Initially, rates were considerably higher among infants from low-income neighbourhoods, but income-specific rates converged over time among eligible infants &lt;6 months; such convergence was not seen among other children.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Incidence of severe RSV-related illness declined over the study period. While we cannot attribute causality, the timing and magnitude of these declines suggest impact of palivizumab in reducing RSV burden and diminishing social inequities among palivizumab-eligible infants.<\/jats:p><\/jats:sec>","DOI":"10.1136\/archdischild-2020-319472","type":"journal-article","created":{"date-parts":[[2020,8,28]],"date-time":"2020-08-28T21:20:27Z","timestamp":1598649627000},"page":"173-179","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":10,"title":["Palivizumab\u2019s real-world effectiveness: a population-based study in Ontario, Canada, 1993\u20132017"],"prefix":"10.1136","volume":"106","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2767-6476","authenticated-orcid":false,"given":"Tiffany","family":"Fitzpatrick","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James Dayre","family":"McNally","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Therese A","family":"Stukel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey C","family":"Kwong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew S","family":"Wilton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Fisman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Astrid","family":"Guttmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2020,8,28]]},"reference":[{"key":"2024100701402729000_106.2.173.1","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2013-0303"},{"key":"2024100701402729000_106.2.173.2","doi-asserted-by":"crossref","DOI":"10.1186\/1472-6963-12-451","article-title":"Acute care utilization due to hospitalizations for pediatric lower respiratory tract infections in British Columbia, Canada","volume":"12","author":"Santibanez","year":"2012","journal-title":"BMC Health Serv Res"},{"key":"2024100701402729000_106.2.173.3","doi-asserted-by":"publisher","DOI":"10.1097\/01.inf.0000137568.71589.bd"},{"key":"2024100701402729000_106.2.173.4","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2458-11-S3-S30","article-title":"An evaluation of the emerging interventions against Respiratory Syncytial Virus (RSV)-associated acute lower respiratory infections in children","volume":"11(Suppl 3)","author":"Nair","year":"2011","journal-title":"BMC Public Health"},{"key":"2024100701402729000_106.2.173.5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0804877"},{"key":"2024100701402729000_106.2.173.6","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1111\/irv.12443","article-title":"Estimating the burden of respiratory syncytial virus (RSV) on respiratory hospital admissions in children less than five years of age in England, 2007-2012","volume":"11","author":"Reeves","year":"2017","journal-title":"Influenza Other Respir Viruses"},{"key":"2024100701402729000_106.2.173.7","doi-asserted-by":"publisher","DOI":"10.1586\/eri.11.92"},{"key":"2024100701402729000_106.2.173.8","first-page":"474","article-title":"Palivizumab and respiratory syncytial virus immune globulin intravenous for the prophylaxis of respiratory syncytial virus infection in high risk infants","volume":"4","year":"1999","journal-title":"Paediatr Child Health"},{"key":"2024100701402729000_106.2.173.9","doi-asserted-by":"publisher","DOI":"10.1016\/j.prrv.2009.06.002"},{"key":"2024100701402729000_106.2.173.10","first-page":"769","article-title":"Palivizumab for the prevention of respiratory syncytial virus infection","volume":"56","author":"Rogovik","year":"2010","journal-title":"Can Fam Physician"},{"key":"2024100701402729000_106.2.173.11","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1093\/pch\/20.6.321","article-title":"Preventing hospitalizations for respiratory syncytial virus infection","volume":"20","author":"Robinson","year":"2015","journal-title":"Paediatr Child Health"},{"key":"2024100701402729000_106.2.173.12","doi-asserted-by":"crossref","first-page":"e10","DOI":"10.1155\/2011\/493056","article-title":"A decade of respiratory syncytial virus epidemiology and prophylaxis: translating evidence into everyday clinical practice","volume":"18","author":"Paes","year":"2011","journal-title":"Can Respir J"},{"key":"2024100701402729000_106.2.173.13","doi-asserted-by":"crossref","first-page":"177","DOI":"10.2165\/00148581-200406030-00004","article-title":"Palivizumab: a review of its use as prophylaxis for serious respiratory syncytial virus infection","volume":"6","author":"Fenton","year":"2004","journal-title":"Pediatr Drugs"},{"key":"2024100701402729000_106.2.173.14","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1093\/pch\/8.10.631","article-title":"Use of palivizumab in children with congenital heart disease","volume":"8","year":"2003","journal-title":"Paediatr Child Health"},{"key":"2024100701402729000_106.2.173.15","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2014-1665"},{"key":"2024100701402729000_106.2.173.16","doi-asserted-by":"publisher","DOI":"10.2174\/1874285801105010144"},{"key":"2024100701402729000_106.2.173.17","doi-asserted-by":"crossref","first-page":"e290","DOI":"10.1097\/INF.0000000000000922","article-title":"Adherence to Palivizumab for respiratory syncytial virus prevention in the Canadian registry of Palivizumab","volume":"34","author":"Chan","year":"2015","journal-title":"Pediatr Infect Dis J"},{"key":"2024100701402729000_106.2.173.18","doi-asserted-by":"crossref","first-page":"195","DOI":"10.2147\/PPA.S5696","article-title":"Compliance with RSV patient prefer adherence","volume":"3","author":"Anderson","year":"2009","journal-title":"Patient Prefer Adherence"},{"key":"2024100701402729000_106.2.173.19","unstructured":"ICES . Data Repository [Online]. Available: http:\/\/datadictionary.ices.on.ca\/ [Accessed 19 May 2015]."},{"key":"2024100701402729000_106.2.173.20","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0150416","article-title":"Incidence of hospitalization for respiratory syncytial virus infection amongst children in Ontario, Canada: a population-based study using validated health administrative data","volume":"11","author":"Pisesky","year":"2016","journal-title":"PLoS One"},{"key":"2024100701402729000_106.2.173.21","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2458-14-1191","article-title":"Contribution of respiratory tract infections to child deaths: a data linkage study","volume":"14","author":"Hardelid","year":"2014","journal-title":"BMC Public Health"},{"key":"2024100701402729000_106.2.173.22","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1185\/03007990902929112","article-title":"Risk-Scoring tool for respiratory syncytial virus prophylaxis in premature infants born at 33-35 completed weeks' gestational age in Canada","volume":"25","author":"Paes","year":"2009","journal-title":"Curr Med Res Opin"},{"key":"2024100701402729000_106.2.173.23","article-title":"Expert consensus on palivizumab use for respiratory syncytial virus in developed countries","volume":"33","author":"Luna","year":"2020","journal-title":"Paediatr Respir Rev"},{"key":"2024100701402729000_106.2.173.24","unstructured":"Ontario Ministry of Health (MOH) . Respiratory syncytial virus prophylaxis for high-risk infants program, 2018. Available: http:\/\/www.health.gov.on.ca\/en\/pro\/programs\/drugs\/funded_drug\/fund_respiratory.aspx [Accessed 11 Feb 2019]."},{"key":"2024100701402729000_106.2.173.25","first-page":"1","article-title":"Development and validation of a simple algorithm to estimate common gestational age categories using standard administrative birth record data in Ontario, Canada","author":"Fitzpatrick","year":"2020","journal-title":"J Obstet Gynaecol"},{"key":"2024100701402729000_106.2.173.26","unstructured":"Howson CP , Kinney MV , Lawn J . Born too soon: the global action report on preterm birth. Geneva: March of Dimes, PMNCH, Save the Children, World Health Organization, 2012."},{"key":"2024100701402729000_106.2.173.27","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2013-3875"},{"key":"2024100701402729000_106.2.173.28","first-page":"119","article-title":"Children with hemodynamically significant congenital heart disease can be identified through population-based registers","volume":"7","author":"Bergman","year":"2015","journal-title":"Clin Epidemiol"},{"key":"2024100701402729000_106.2.173.29","unstructured":"Kralj B . Measuring Rurality - RIO2008_BASIC: Methodology and Results, Ontario Medical Association Economics Department, 2009. Available: https:\/\/www.oma.org\/wp-content\/uploads\/2008rio-fulltechnicalpaper.pdf [Accessed 9 Aug 2019]."},{"key":"2024100701402729000_106.2.173.30","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2710.2002.00430.x"},{"key":"2024100701402729000_106.2.173.31","doi-asserted-by":"publisher","DOI":"10.1503\/cmaj.101371"},{"key":"2024100701402729000_106.2.173.32","doi-asserted-by":"publisher","DOI":"10.1097\/INF.0b013e31821146f7"},{"key":"2024100701402729000_106.2.173.33","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0205399","article-title":"Population-based trends and underlying risk factors for infant respiratory syncytial virus and bronchiolitis hospitalizations","volume":"13","author":"Bennett","year":"2018","journal-title":"PLoS One"},{"key":"2024100701402729000_106.2.173.34","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0152208","article-title":"Trends in respiratory syncytial virus and bronchiolitis hospitalization rates in high-risk infants in a United States nationally representative database, 1997-2012","volume":"11","author":"Doucette","year":"2016","journal-title":"PLoS One"},{"key":"2024100701402729000_106.2.173.35","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2012-3877"},{"key":"2024100701402729000_106.2.173.36","doi-asserted-by":"crossref","unstructured":"Jalink M , Langley JM . The palivizumab patchwork: variation in guidelines for respiratory syncytial virus prevention across Canadian provinces and territories. Paediatr Child Health. In Press;394.doi:10.1093\/pch\/pxz166","DOI":"10.1093\/pch\/pxz166"},{"key":"2024100701402729000_106.2.173.37","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpeds.2006.04.063"},{"key":"2024100701402729000_106.2.173.38","unstructured":"National Collaborating Centre for Healthy Public Policy . Thirteen public interventions in Canada that have contributed to a reduction in health inequalities, 2010. Available: http:\/\/www.ncchpp.ca\/docs\/13interventions_inequalities_en_sansisbn_final.pdf [Accessed 22 May 2019]."},{"key":"2024100701402729000_106.2.173.39","article-title":"CARESS: the Canadian registry of Synagis","volume":"93","author":"Lanctot","year":"2008","journal-title":"Arch Dis Child"},{"key":"2024100701402729000_106.2.173.40","unstructured":"Crowe K . Provinces spent $43M on preemie drug experts say can be made for a fraction of the cost, CBC, 2017. Available: https:\/\/www.cbc.ca\/news\/health\/rsv-drug-synagis-palivizumab-premature-infants-abbvie-provinces-health-care-1.4056823 [Accessed 22 May 2019]."}],"container-title":["Archives of Disease in Childhood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/archdischild-2020-319472","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,7]],"date-time":"2024-10-07T08:44:07Z","timestamp":1728290647000},"score":1,"resource":{"primary":{"URL":"https:\/\/adc.bmj.com\/lookup\/doi\/10.1136\/archdischild-2020-319472"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,28]]},"references-count":40,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2021,1,19]]},"published-print":{"date-parts":[[2021,2]]}},"alternative-id":["10.1136\/archdischild-2020-319472"],"URL":"https:\/\/doi.org\/10.1136\/archdischild-2020-319472","relation":{},"ISSN":["0003-9888","1468-2044"],"issn-type":[{"value":"0003-9888","type":"print"},{"value":"1468-2044","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,28]]}}}